Although this term has pro ven useful, definiti on of a specific disease state on the basis of a single clinical sign is fraught with hazard . Frequent but variable involvement of non ocular tissues has added to the complexity of a strictly clinical diagnosis of CPEO . Kiloh and Nevin (I ) considered CPEO to be a distinctive myopath ic syndrome, with relati vely isolated myopathy of the extraocular muscles, and only occasional mild weakness in the extremities. However, it became apparent that many CPEO pat ients had evidence of multisystem disease (2) (3) (4) . There can be pigmentary degener ation of the retina, optic atrophy, cerebellar ataxia, sensorineural hearing loss, peripheral neuropathy, electroencephal ographi c abnormalities, and/or elevation of protein content of the cerebrospinal fluid. Less frequentl y, there are pyramid al or extrapyram idal signs, seizures, or frank cogniti ve imp airment. A few path ologic studi es of the nervous system have dem on strated spon giform poliodystrophy.
Although the paresis of the extraocular muscles in CPEO is assumed to be a myopath y, their dysfunction may result from prim ary failure of the nervous stru ctu res that control them (5) . In CPEO, frank ophthalmoparesis is preceded by profound slowing of saccadic eye movements, with relative preservation of pursuit and vestibular eye movements , suggesting involvement of excitatory medium-lead "burst" neurons (6) . The se neurons likely have unusually high energeti c demands, inasmu ch as the y selectively initiate saccadic eye movements with an extremel y rapid volley of electrical discharge.
Cardiac path ology most frequ entl y takes the form of conduction defects, typically intraventri cular bran ch blocks or interventricular block , which, curiously, can be heralded by a period of enhanced A-V nod al conduction (7, 8) . We have also obser ved supraventricular tachycardias and congestive heart failure. Pathologic studies have demonstrated fatty infiltration, fibrosis, and occasional giant mitochondria, both in conducting fibers and elsewhere in the myocardium (9) .
Pathology is not limited to electrically excitable tissues. Renal dysfunction most often involves a proximal tubular defect, with am inoaciduria and phosphaturia-the De Toni-Fanconi-Debre syndrome (3)-but we have also observed glomerulopathy and ren al failure. Proport ionate short stature, scoliosis, and a higharched palate have in some instances been associated with defective release of growth hormone; in others, they have not (3) . Other endocrine dysfunction includes diabetes mellitus , sometim es latent until the patient is stressed by glucocorticoids (10), which had been used by some clinicians to treat these patients. Parathyroid dysfunction has also been described (3) .
In summary, CPEO can present with clinical dysfunction of variabl e severity in a number of highly oxidative organs , reflecting prim ary pathol ogy of tissues derived from man y cell lineages.
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Abbreviations CLINICAL FEATURES O F CPEO CPEO, chronic progressive external ophthalmoplegia MELAS, mitochondrial encephalopathy, lactic acidosis , and stroke-like symptoms MERRF, myoclonic epilepsy with ragged red fibers LHOA, Leber's hereditary optic atrophy ABSTRACf. Chronic progressive external ophthalmoplegia (CPEO) describes a recognizable clinical syndrome frequently associated with variable dysfunction in other organ systems. Hi stochemical and biochemical studies suggested primary dysfunction of oxidative phosphorylation, This has recently been confirmed by demonstration of partially deleted as well as normal mitochondrial DNAheteroplasmy-in some of these patients, most of them sporadic. In the six heteroplasmic CPEO patients that we have examined to date, the partially deleted species has been detected in all tissues tested, albeit in vastly different proportions. We report here detection of physiologicall y significant proportions of partially deleted mitochondrial DNA in several organs taken at autopsy from a CPEO patient with severe multisystem disease. We discuss the relationship of CPEO to several other clinical phenotypes associated with mitochondrial dysfunction, and discuss the possible implications of heteroplasmy for the development of variable phenotypes. (Pediatr Res 28: 542-548, 1990) In strict usage, the term CPEO describes only a clinical signparesis of the muscles that rotat e the eyes in the orbit and elevate the eyelids, with sparing of internal ocular muscles that control the lens and the iris. However, it has also come to connote a specific disease in which such paresis is the predominant clinical findin g. This latter meaning was used interchangeabl y with the terms "mitochondrial m yopath y" or "ragged-red fiber disease," until recent descriptions of oth er clin ical phenotypes associated with similar pathologic and biochemical changes.
Furth ermore, the pattern of organ involvement and severity is notoriously variable. Und erstand ably, this extreme pleiotropy gave rise to a plethora of diagnostic labels: in McKu sick's catalogue, Mendelian Inheritance in Man (II ) , there are over a dozen listings for CPEO with different patterns of organ involvement. Of these, the most enduring has been that of Kearns and Sayre, who proposed that the triad of CPEO, retinal pigmentary degeneration, and heart block constitutes a distinctive syndrome (12) . Several years later, Rowland and his colleagues (5) proposed that such a syndrome is indeed distinctive and that the definition be modified to include ophthalmoplegia, pigmenta ry retinopath y, onset before age 20, and at least one of three other featu res: either high cerebrospinal fluid protein , heart block, or ataxia. A commonly held view is that this expanded definition will distinguish those patients with systemic disease from those who have isolated involvement of the extraocular muscles.
In an earlier clinical review (13, 14) , Drachman proposed a unified concept-ophthalmoplegia plus-lumping together all CPEO patients, whatever the pattern of nonocular disease. Some authors have even included patients without CPEO but with a typical constellation of neural and systemic involvement (3) . Although th is view may seem intellectually unsatisfacto ry-and indeed is demon strably too global-recent genetic and laboratory studies recommend that aspects of this unitary view be reexamined.
BIOCH EMICAL AND MOR PHOLOGIC FEATU RES OF CPEO
Th e idea that many CPEO syndro mes might be variations on the same fundamental theme finds support from laboratory findings indicating primary dysfunction of mitochondrial oxidative phosphorylation. Most studies have been performed on skeletal muscle, because of both historical tradition and practical considerations. However, similar changes have occasionally been observed in other tissues (15) .
Histochem ical and electro n microscopic observation of skeletal muscle dem onstrat es that some, but never all, of type I fibers contain abnormally large collections of mitochondria, the morphology of which may be altered (16) (17) (18) . Similar mit ochondrial alterat ions have been indu ced in experimental animals that were exercised excessively or treated with toxins that interfere with oxidative phosphorylation at any of several biochemical sites. Th ese changes can be prevented with chloramphenicol, a specific inhi bitor of mitochondrial, but not nucleocytoplasmic, protein synthesis (19, 20) . This suggests that these cellular changes are a nonspecific proliferative response to a mismatch between demands for oxidative phosph orylation and the ability to meet these demands.
Some of these mitochond ria may contain as yet biochemically un characterized inclusions, often with a characteristic paracrystalline "parking-lot" morphology (16, 17) . Curiou sly, the majority of fibers, includ ing those immediately adjacent , have no morphologic alterat ions of mitochondri a. This indicates heterogenou s involvement even within the class of type I fibers, all of which are likely expressing identical nuclear-encoded isozymes. An even more telling observation was reported by John MorganHughes and others (2 1-23): serial cross-sections revealed that most ragged-red fibers contain excessive activity of all mitoch ondrial enzymes, as would be expected. However, an occasional fiber showed increased numbers of ragged-red mitochondrial membranes by the Gomo ri trichrome stain and the expected increase of succinate dehydrogenase activity, but compl ete absence of cytochrome oxidase activity.
Biochem ical observations give further support to the hypothesis of defective oxidative phosphorylation. Elevations of lactic acid, although~ild and variable within the same patient, are observed frequently. In several of our CPEO patients, venous levels of lactic acid are normal at rest, but rise abnormally on graded exercise. Such tests are ideally performed with concomitant measurement of cardiac output, oxygen extraction, and consumption, with precise delineation of an anaerobic threshold (24) (25) (26) . However, such tests are laboriou s and commonly requir e invasive catheterization.
A more convenient indir ect measure of oxidative phosphorylation, nuclear magnetic resonan ce spectroscopy of high energy phosphates before and after exercise, has indicated abnormalities in skeletal muscle of man y CPEO patients (27) . Recently, we have used a similar procedure to detect abnormalities of high energy phosphates in the frontal lobes of five patients with dissimilar mitochondrial encephalomyopathy phenotypes (28), among them two patient s with different CPEO syndromes with no clinically evident dysfunction of the telenceph alon .
Further indirect evidence implicating mitochondrial dysfunction in CPEO and other ragged-red syndromes comes from reports of improvement after treatment with agents that might correct defective oxidative phosphorylation or its immediate consequences (29) (30) (31) (32) : cofactors for the protein components of the electron transport chain ; "electron shuttles," substituting for a defective respiratory chain component, or scavengers of toxic free radicals that could accumulate in high ambient oxygen concentrations. Although isolated reports of clinical improvement have been impre ssive and , in some cases supported by spectroscopic, electrophysiologic, and/or lactate measurem ents , some of us have been disappoint ed in our ability to intervene successfully in the majority of our patient s.
More direct assessments of mitochondrial function support further the idea of defective oxidative phosphorylation in CPEO , but even these assays can be problematic. Our current preference is for polarographic anal ysis of intact fresh mitochond ria harvested from biopsied muscle (33, 34) . Unfortunately, this requir es a large biopsy specimen and , ideally, assay of nonfrozen material. The isolation of intact mitochondri a from skeleta l muscle-a tough, fibrillar tissue-is a delicate procedu re: artifactual uncoupling (i .e. mimicking the biochemical phenotype of Luft' s disease) can occur with minor variations in the homogenization procedure. Furtherm ore, polarograph y is rout inely performed at ambient atm ospheric oxygen concentrations, considerably higher than those encountered by most mitochond ria in vivo.Finally, there is the problem of studying a mixture of norm al and abnormal mitochondria.
Given these considerations, only equivocal alterations in oxidative phosphorylation have been found in many CPEO patients, even those in whom there is other indirect evidence of mitochondrial dysfunction. However, certain CPEO patients have demonstrated dysfunction in man y sites along the electron transport chain. Complex I (NADH-coenzyme Q reductase ) dysfunction has been found in a typical CPEO syndrome (35, 36) as well as a case in which paresis of vergence and upgaze only were minor features of a moderately severe, generalized myopath y (37); other CPEO patients had part ial deficiency of complex IV (cytochrome oxidase) (2 1-23), sometimes with increased levels of cytochrome c (34) . Complex III deficiency was observed in a father and son, only the latter having CPEO (38); a child with myopath y and ptosis but no other ophthalmoparesis (39) was reported to have severe deficiency of complex II (succinate dehydrogenase), the only respiratory complex that does not contain subunits encoded by mitochondri al DNA.
Conversely, dysfunction of a given site along the electro n transport chain has been associated with man y seemingly disparate clinical phenotypes (40, 41) : some cases of norm oglycemic congenital lactic acidosis (42) (43) (44) (45) ; individual cases with Leigh's polioencephalopathy (46) (47) (48) ; MELAS syndrome (49-51); MERRF syndrome (26, (52) (53) (54) (55) ; and proximal myopath y with easy fatiguability (2) . Despite their biochemical and histologic similarities, they have been described as distinct clinical syndromes. However, upon following patients for several years, we have observed several instances of individuals progressing from one syndrome to another: a 34-y-old patient with MELAS who later developed typical CPEO and retinal pigmentary degeneration (Fig. 1) ; another 34-y-old in whom CPEO preceded the H URKO E T A L. development of the MERRF syndrom e by 6 y; and a patient who succumb ed at age 23 after developing sequentially CPEO and pigmentary retinopathy, MELAS, and terminall y, the MERRF syndrome.
These observations suggest that the clinical phenotype reflects more accurately the degree of impairment of flux throu gh the entire electron tran sport chain and the anatomic distribut ion of abnormal mitochond ria, rather than the precise biochemical site at which such flux is impaired.
GE NET IC AN D MOL ECUL AR O BSER VATIO NS ON CPEO
The majority of CPEO patients are sporadic. Many CPEO patients with severe multisystem involvement are too ill to have children. However, one of our CPEO patients [a 52-y-old woman with partial deletions of mitochondrial DNA detected in skeletal muscle and peripheral blood (56) ] has three healthy children in college. Small pedigrees with multiple individu als affected with CPEO have also been encountered (20, (57) (58) (59) . In most of these pedigrees, including our own, CPEO has been tran smitted along the maternal lineage. There have also been cases of paternal transmission of mitochondrial CPEO with systemic involvement to a son (3, 38, 59) , suggesting involvement of an autosomal nuclear gene in those kindreds.
Speculation about the possible role of mitochond rial DNA in the pathogenesis of some ragged red syndromes was initially based on consideration of biochemical and morphol ogic abnormalities (60). More compelling, albeit inconclusive, evidence came from tran smission genetics. Small pedigrees compatible with mitochondrial inheritance were published in a seminal paper by Egger and Wilson (59) . In several of these pedigrees some affected individuals had ophthalmoparesis, but otherspresumably affected by the same mutati on-only had clinically apparent disease in other organ systems. Egger and Wilson presciently speculated that such variable organ involvement within a given family might reflect random segregation of normal and mut ant mitochondria within a given individu al. We have encount ered such dramatic pleiotropy in one kindred that is segregating cytochrome oxidase deficiency (49) .
Although mutations of either mitochondri al or nuclear genes may result in a CPEO or related phenotype, until recently the evidence for involvement of mitochondrial DNA in CPEO was inconclusive. In small pedigrees, one would expect occasional chance occurrence of strictly maternal transm ission; man y heritable diseases that exhibit pleiotropy and phenotypic variability within the same pedigree have impeccable credentials as autosomal dominant trait s. The earliest direct evidence that a mitochondrial mutation was responsible for a case of CPEO came from Byrne et al. (61) , who observed an altered electrophoretic mobility of a mitochondrial translation produ ct in skeletal muscle. More direct evidence for mitochondrial DNA mutati ons in some instances of CPEO was provided by Holt, Harding, and Morgan-Hughes (62, 63) , who demonstrated partial deletions in a subpopulation of mitochondrial DNA extracted from skeletal muscle. To their initial reports have been added others, including six of our own (56, (64) (65) (66) (67) (68) (69) (70) . Most reported cases of mitochondrial DNA deletions, including all of ours, have come from patients with a sporadic CPEO syndrome, some of them fulfilling diagnostic criteria for the Kearns-Sayre syndrom e, others not. No correlation between the size or molecular location of the deletion and the pattern of organ involvement is apparent. Indeed, this is not unexpected as most reported deletions associated with CPEO remove genes encoding components of the electron tran sport chain and also several tran sfer RNA genes. All but two of our patients have different deletions and all but one involve directly repeated sequences at the deletion jun ctions, the consensus of which resembles putative recombi nation signals (69, 70) .
In all reported CPEO patients with partial deletions of mitochondrial DNA detected by Southern analysis, the partially deleted species were not found in blood cells. However, using a more sensitive assay (58, 68, 69) we and others have observed some partially deleted mitochondrial DNA molecules in all tissues tested from each such patient, albeit in vastly different proportions (56, 69, 70) . This procedure is a modification of the standard polymerase chain reaction, using oligonucleotide primers with recognition sites widely spaced on normal mitochondrial DNA but closely bracketing the deleted region. It selectively amplifies deletion junctions even when norm al, undeleted mitochondrial DNA is present in 1000-fold excess (69) . As currently performed, it does not permit precise quantitation; we can only infer that partially deleted mitoc hondrial DNA is a very minor species in the blood and urinary epithelial cells of those CPEO patients tested to date, because we can detect it by the polymerase chain reaction but not by Southern anal ysis. Although the small amo unts of partially deleted species in blood and epithelium seem well below the threshold necessary for clinically significant disruption of oxidati ve phosp horylation in those cells, their presence clearly indica tes that the origin of the mutation in these patients ante ceded divergence of the muscle lineage. Thus , physiologically significant replacement of normal by mutant mitochondrial DNA is possible in tissues derived from an y of the three primary cell layers.
Our only direct evidence on this point comes from Southern analysis on multiple tissues from an autopsied case, whose clinical and biochemical features were reported elsewhere (34, case I). We report here th at different proportions of part ially deleted and normal mitochondrial DNA were readily detectable by Southern analysis of skeletal muscle, brain, heart, liver, and kidney (Fig. 2) . The decrease in oxidative activity measured polarograp hically in these tissues paralleled the ran k order of increasing proportion of part ially deleted mitochondrial DNA in all tissues but the liver, which was presumed to be autolyzed by the time of polarography. There was clinically evident dysfunction of skeletal muscle, heart , and brain , but liver and kidne y were judged normal in vivo. In all tissues, the partiall y deleted species were identical , indicating common descent from a single mutational event. The se observation s, albeit limited, suggest that different patterns of organ involvement in CPEO patients may be, in part, quantitative rather than qualitative. What may matter Wild type and parti ally deleted m itochondrial DNA spec ies in various organs harvested at autopsy from a child with CPEO and multi system disease. a. Southern blot of total cellu lar DNA restricted with BamHI, subjec t to electrophoresis on 1.1% agarose, transferred to nit rocellulose, hyb ridized with a clon ed probe (prepared from HeLa mi tochondrial DNA, nucle otides 16453 to 3245) that had been made radi oacti ve by ran dom-primer labeling , and visualize d by autoradiograph y. b, Proportions of partiall y deleted species, as estimated by laser densit om etr y and expressed as a perc ent age of total mitochondrial circles. most in these patients is not which region of the mito chondrial DNA is deleted, but how man y normal mitochondria remain in a given cell. Indeed , several patient s with Pearson's syndrome (infantile aplastic anemia and pancreatic failure) have a subpopulation of mitochondrial DNA with deletio ns identical at the molecu lar level to three of our adult CPEO patients, but with differing tissue distributions (7 1, 72 ).
An interesting contrast can be made between the ragged-red fiber syndromes described above, and another heritable disorder affecting oxidative phospho rylation , LHOA , discussed earlier in this symposium by Dr. Douglas Wallace. Although biochemical and histologic evidence of mitochondrial dysfunction in the ragged-red syndromes is strong , evidence from transmission genetics is indirect and inconclusive. In contrast, the majo r evidence of mitochondrial involvement in LHOA comes from compelling dat a in transmission genetics (73, 74) , whereas biochemical and histochemical evidence of mitochondrial dysfunction is weak or lacking: lactate levels are normal, as are most polarogra phic and enzymatic studies of isolated mit ochondria, and equivocal alterations of mitochondrial morphology are onl y evident in some electron microscopic studies (75) . Definite proof of a minor oxidative phosphorylation defect in LHOA come s from Wallace's elegant association of a point mutation in a conser ved region of a mitochondrial gene encoding a subunit of respiratory complex I (76). Furthermore, unlike those individuals with a ragged-red syndrome associated with a mutation in mitochondrial DNA, man y LHOA patients appear homoplasmic for the mutant mitochondrial DNA species in all tissues tested to date .
T HEORETI CAL CO NSIDERATIONS
Oxidative phosphorylation is such a fundamentally important process that it appears un likely that a mutation completely disrupting the electron transport chain in every cell in the bod y will permit extrauterine life. Therefore, patients harboring mutations that affect oxidative phosphorylation must fall into one of two categories. 1) Those patients with mutations that completely disrupt oxidat ive phosphorylation must also contain a complement of normally functioning mitochondria to sustain life. Tissues with a large complement of dysfunctional mitochondria would be am enable to biochemical diagnosis. This seems true in those CPEO patie nts with large partial deletions of mitochondrial DNA. 2) Those mutations expressed in every mitochondrion in the body must disrupt oxidative metabolism onl y minimally. Therefore, direct biochemical verification of th e abn ormality may prove difficult. This appears true in those cases ofLHOA in which a pathogen ic point mutation has been determined .
In both situations, clinical involvement of some tissues but not others could result from a number of possible mechanisms. These include: 1) differing requirements for oxidative metabolism in individual tissue types, which ma y change with activit y and develop ment; 2) involvem ent of nuclear-encoded components of the electron transport chain or other regulatory prot eins, some of which exist as tissue-specific isoforms (77); and 3) interaction with variable , nongenetic en vironmental factors. Our discussion will be limited to the possible relationship of another factor-heteroplasmy, the presence of more than one type of mitochondrial DNA in an individual organism-to the clinical heterogeneity evident in CPEO and other ragged red syndromes.
In somatic cells of mammals, each mitochondrion contains about six loops of mitochondrial DNA (78) , each a separate genetic unit; a mutation in one such mitoc hondrial genome will affect directly only itself and its daughter molecules. Because each somatic cell contains tho usands of such molecules, it appears unlikely that such a mutation would significantly affect cellular metabolism un less it came to represent a major popu lation. Such threshold effects of mitochondrial mutants conferring resistance to chloramphenicol have been demonstrated (79, 80), Fig. 3 . During early embryogenesis, the total number of mitochondria does not increase, but the subdivision of the fertilized zygote into a large number of cells sequesters small groups of adjacent mitochondria. Only a few of thesecells give rise to the final embryo. Bychance, certain cells acquire mostly mutant mitochondria (darkened ovals). Thus. a previously minor population of mutant species may become predominant in certain cell lineages.
and it appears likely th at other mitochondrial mutants will beha ve similarly.
How daughters of a single mutant molecule can become a physiologically significant population in certain cell lineages may be und erstood by consid eration of early embryonic development, during which the large cellular complem ent of mitochondrial DNA becom es sequestered into man y sma ller pool s. Du rin g fem ale gametoge nesis, the ploidy of an individ ual mitochondrion becom es redu ced to about one. After fertilization of the egg, the first few cleavage division s occur without growth of the zygote or apparent replicat ion of mit ochondria, with the total nu mber of mit ochondria in the zygote remaining fixed (Fig. 3) . T hus, a minor popul ation of mutant mitochondria in th e original ovum may, by chance, becom e a major popul ation in certai n cells of the blastocyst. Thus, it seems likely that stem cells of various cell lineages may, at rand om, receive different proportions of normal and mutant mitochondria. The relativ e proportions of normal and mutant mitochondria in adult tissues, may, in part , reflect the proporti ons contained in their progenit or cells.
In mammals, only a few cells in the blastocyst give rise to th e embryo; most others are troph oblastic, and are thu s eventually discarded. It is by th is mechani sm that hom oplasmy is usually maintain ed (8 1) . In studies of cows with nonpathogenic polymorphisms of mitochondrial DNA, Laipi s, Hauswirth , and colleagues (82-85) docum ent ed occasional transitions to heteroplasm y, as well as rap id shifts between one apparently hom oplasmi c state and another. Because these shifts occur in the absen ce of any obvious selective pressure, th ey presumab ly result from rand om mitotic drift and embryonic sequestration.
Similar pro cesses ma y occur in patients with pathogen ic mutations of mitochondrial DNA , with added complexity superimposed by various selective pressure s. In th e specific case of partiall y deleted mit ochondrial DN A, different selective pressures may be exerted at different levels of organization. At the level of an individual molecule with int act origins of replicat ion, the deleted species, being smaller, may enjo y a replicative adva ntage over its intact, wild type counterpa rts. T his effect would be most evide nt in postmitotic tissues, allowing gradu al selecti ve accumulat ion th rough out life. At the level of the cell, selection ma y be a function of the proportion of normal mitochondria and the oxidative dem ands on a particular cell. Early mammalian embryogenesis in the fallopian tubes and shortly after im plantation occurs at low oxygen concentrations. Thus, mutation s affecting oxidati ve phosphorylation ma y be selectively neutral during th e early seq uestration and sorting of mit ochond ria described above. Ho wever, at later stages, whenever a part icular cell's capacity for oxida tive metabolism d rops below a critical thresh old, one ma y expect negative selectio n, poor growt h or possibly death of the cell. Cells th at rem ain mitotically active throughout life, such as blood and epithelium, are more likely to generate , th rough rando m drift , populations with skewed representation of either nor mal or mutant species, and on whom such selection may be exaggerated. How ever , above a criti cal threshold of oxidati ve capacity, one might expect positive selective pressure-preferential proliferation of all mitochondria in th ose cells with some defecti ve organelles-because cells can respond to a mismatch between oxida tive capacity and demand by ind ucing mit ochondrial proliferation and increasing cellular ploid y of mit ochondrial D NA (86, 87) . We speculate that such selective mitochondrial proliferation ma y acco unt for the form ation of ragged red fibers. Furtherm ore, rare deletion events in m itoc ho ndrial DN A of postm itotic tissues such as heart or brain ma y become selectively amplified in the course of norm al aging.
Evaluation of th e relative roles of random drift and the effects of such proposed selective pressures (80) in the production of the final phenotype associated with heteroplasmic m itochondrial DNA mutations is an intriguing and difficult probl em . Is there som ething peculiar to skeletal mu scle and brain th at invites selective proliferati on of mutant mitochond ria or is this sim ply ascertainment bias-patients with mitochondrial dysfun ction predominatin g in other organs either not survi ving or not being recognized? Excellent mathematical paradigms for analyzing such problem s have already been developed by population biologists (88) ; biochem ical and molecular measure s such as the ones discussed in this symp osium will be invaluable in testing such models.
"One cannot separate theory from observation, or perhaps more precisely, one must have a theory, however vague it m ay be. "-0. Kempthorne.
